Cargando…
Targeting G(1)/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
BACKGROUND: Although CDK4/6 inhibitors are an established treatment for hormone receptor–positive, HER2-negative metastatic breast cancers, their benefit in other malignancies remains limited. METHODS: We investigated factors associated with clinical outcomes from CDK4/6 inhibitor–based therapy amon...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Clinical Investigation
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821594/ https://www.ncbi.nlm.nih.gov/pubmed/33427211 http://dx.doi.org/10.1172/jci.insight.142547 |